Corvus Pharmaceuticals (CRVS) News Today $7.39 +0.49 (+7.10%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Corvus Pharmaceuticals Shares Rise 14% Ahead of Soquelitinib Trial Data RevealDecember 18 at 1:38 AM | marketwatch.comCorvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024December 17 at 4:01 PM | globenewswire.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Sees Large Increase in Short InterestCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) was the target of a significant growth in short interest in November. As of November 30th, there was short interest totalling 3,510,000 shares, a growth of 6.4% from the November 15th total of 3,300,000 shares. Based on an average trading volume of 771,600 shares, the days-to-cover ratio is presently 4.5 days.December 17 at 2:41 PM | marketbeat.comIndividual investors account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while private equity firms account for 16%December 11, 2024 | sg.finance.yahoo.comPoint72 Asset Management L.P. Has $29.37 Million Holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)Point72 Asset Management L.P. trimmed its stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 6.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,562,729 shares of the compDecember 6, 2024 | marketbeat.comCorvus publishes data on potential of soquelitinib to modulate tumor activityDecember 5, 2024 | markets.businessinsider.comConnor Clark & Lunn Investment Management Ltd. Has $724,000 Stock Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)Connor Clark & Lunn Investment Management Ltd. raised its position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 64.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 137,031 shaNovember 29, 2024 | marketbeat.comFY2024 EPS Estimates for CRVS Decreased by Cantor FitzgeraldCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Stock analysts at Cantor Fitzgerald decreased their FY2024 earnings per share (EPS) estimates for shares of Corvus Pharmaceuticals in a report released on Wednesday, November 13th. Cantor Fitzgerald analyst L. Watsek now anticipates thatNovember 18, 2024 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Sees Unusually-High Trading Volume - What's Next?Corvus Pharmaceuticals (NASDAQ:CRVS) Sees Strong Trading Volume - Here's What HappenedNovember 15, 2024 | marketbeat.comAn Intrinsic Calculation For Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Suggests It's 41% UndervaluedNovember 14, 2024 | finance.yahoo.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Sold by Towerview LLCTowerview LLC decreased its holdings in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 70.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 117,500 shares of the company's stock aftNovember 14, 2024 | marketbeat.comCorvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic SclerosisNovember 14, 2024 | globenewswire.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | msn.comCorvus Pharmaceuticals: The Market Likes The StoryNovember 13, 2024 | seekingalpha.comCorvus Pharmaceuticals (NASDAQ:CRVS) Price Target Raised to $14.00 at OppenheimerOppenheimer lifted their price objective on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an "outperform" rating in a report on Wednesday.November 13, 2024 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up Following Analyst UpgradeCorvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up Following Analyst UpgradeNovember 13, 2024 | marketbeat.comCorvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ...November 13, 2024 | finance.yahoo.comCorvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial ResultsNovember 12, 2024 | globenewswire.comCorvus Pharmaceuticals (NASDAQ:CRVS) Reaches New 12-Month High - What's Next?Corvus Pharmaceuticals (NASDAQ:CRVS) Reaches New 12-Month High - Time to Buy?November 11, 2024 | marketbeat.comCorvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate CancerNovember 9, 2024 | globenewswire.comCorvus Pharmaceuticals options imply 12.0% move in share price post-earningsNovember 6, 2024 | markets.businessinsider.comCorvus Pharmaceuticals (CRVS) Scheduled to Post Earnings on TuesdayCorvus Pharmaceuticals (NASDAQ:CRVS) will be releasing earnings after the market closes on Tuesday, November 12, Zacks reports.November 6, 2024 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Reaches New 1-Year High - Still a Buy?Corvus Pharmaceuticals (NASDAQ:CRVS) Reaches New 12-Month High - Here's WhyNovember 5, 2024 | marketbeat.comCorvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024November 5, 2024 | globenewswire.comCorvus Pharmaceuticals (NASDAQ:CRVS) Sees Unusually-High Trading Volume - Time to Buy?Corvus Pharmaceuticals (NASDAQ:CRVS) Sees Large Volume Increase - Should You Buy?November 4, 2024 | marketbeat.comStockNews.com Downgrades Corvus Pharmaceuticals (NASDAQ:CRVS) to SellStockNews.com downgraded Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday.October 31, 2024 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Reaches New 12-Month High - Time to Buy?Corvus Pharmaceuticals (NASDAQ:CRVS) Hits New 12-Month High - Time to Buy?October 28, 2024 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Trading Up 6% - Should You Buy?Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 6% - Still a Buy?October 25, 2024 | marketbeat.comMizuho Upgrades Corvus Pharmaceuticals (NASDAQ:CRVS) to Strong-BuyMizuho raised shares of Corvus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday.October 24, 2024 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Lifted to "Hold" at StockNews.comStockNews.com raised Corvus Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday.October 23, 2024 | marketbeat.comCorvus Pharmaceuticals upgraded to Outperform from Neutral at MizuhoOctober 22, 2024 | markets.businessinsider.comCorvus Pharmaceuticals (NASDAQ:CRVS) Sets New 52-Week High - Should You Buy?Corvus Pharmaceuticals (NASDAQ:CRVS) Reaches New 52-Week High - Time to Buy?October 22, 2024 | marketbeat.comInsiders of Corvus Pharmaceuticals Getting Good Value On Their US$1.03m InvestmentOctober 18, 2024 | finance.yahoo.comShort Interest in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Expands By 31.1%Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) saw a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 2,150,000 shares, a growth of 31.1% from the September 15th total of 1,640,000 shares. Based on an average daily volume of 398,000 shares, the short-interest ratio is presently 5.4 days.October 15, 2024 | marketbeat.comPoint72 Asset Management L.P. Takes Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)Point72 Asset Management L.P. acquired a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 5,964,510 shares of the company's stock, valued at approximOctober 1, 2024 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Downgraded to "Sell" at StockNews.comStockNews.com lowered shares of Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday.September 27, 2024 | marketbeat.comSamlyn Capital LLC Purchases 3,774,658 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)Samlyn Capital LLC grew its position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 160.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,123,021 shares of the company's stock aftSeptember 24, 2024 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Price Target Raised to $21.00LADENBURG THALM/SH SH lifted their price objective on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a "buy" rating in a report on Monday.September 16, 2024 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Raised to Hold at StockNews.comStockNews.com raised Corvus Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Friday.September 13, 2024 | marketbeat.comCorvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell LymphomaSeptember 10, 2024 | globenewswire.comCorvus Pharmaceuticals Inc.September 9, 2024 | barrons.comCorvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | globenewswire.comCorvus Pharmaceuticals Inc (CRVS)August 20, 2024 | investing.comVanguard Group Inc. Increases Holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)Vanguard Group Inc. lifted its holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 10.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,493,357 shares of the company's stock after purchasing anAugust 20, 2024 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPSCorvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.05. During the same quarter in the prior year, the company posted ($0.14) EPS.August 9, 2024 | marketbeat.comCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial ResultsAugust 6, 2024 | globenewswire.comCorvus Pharma Gets FDA's Fast-Track for Lymphoma TreatmentAugust 1, 2024 | marketwatch.comCorvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)August 1, 2024 | globenewswire.comCorvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024July 31, 2024 | globenewswire.com Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Could this be the hottest crypto discovery of all time? (Ad)I want to let you in on what may be the hottest crypto discovery of all time… One that has NOTHING to do with creating a crypto wallet or touching ANY risky coin for that matter. Instead, it’s a way that could let regular folks like you and me target 10X the possible results you’d expect from buying Bitcoin … in just a fraction of the time It sounds nuts… trust me I know that… But just as I would hate for you to jump into any risky crypto asset… That’s exactly how I would hate for you to miss out on what could be a safer and better way to benefit from the crypto bull run of 2024. Which is why I’m giving you an opportunity to get all the details of this iconic crypto discovery with you for the first time ever… completely free… If you want in, Just Click Here CRVS Media Mentions By Week CRVS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRVS News Sentiment▼0.380.71▲Average Medical News Sentiment CRVS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRVS Articles This Week▼52▲CRVS Articles Average Week Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Galapagos News Xencor News Evotec News Arcutis Biotherapeutics News Arcus Biosciences News Nurix Therapeutics News Kiniksa Pharmaceuticals News Immunocore News Ocular Therapeutix News Mesoblast News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRVS) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRVS Stock Alerts